The Technical Analyst
Entera Bio Ltd [ENTX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Entera Bio Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals
-3.38% $2.00
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 70.96 mill |
| EPS: | -0.310 |
| P/E: | -6.45 |
| Earnings Date: | May 03, 2024 |
| SharesOutstanding: | 35.48 mill |
| Avg Daily Volume: | 0.230 mill |
| RATING 2024-04-25 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -6.45 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.10x |
| Company: PE -6.45 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.366 (-81.68%) $-1.634 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.804 - 2.20 ( +/- 9.80%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-19 | Yaacov-garbeli Dana | Buy | 130 000 | Stock Option (right to buy) |
| 2024-04-19 | Yaacov-garbeli Dana | Buy | 30 151 | Ordinary Shares, par value NIS 0.0000769 per share |
| 2024-04-19 | Galitzer Hillel | Buy | 130 000 | Stock Option (right to buy) |
| 2024-04-19 | Galitzer Hillel | Buy | 30 151 | Ordinary Shares, par value NIS 0.0000769 per share |
| 2024-01-12 | Taitel Haya | Buy | 9 500 | Ordinary Shares, par value NIS 0.0000769 per share |
| INSIDER POWER |
|---|
| 100.00 |
| Last 93 transactions |
| Buy: 4 653 836 | Sell: 4 161 674 |
Forecast:
16:00 - $2.01
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.01
Forecast 2: 16:00 - $2.01
Forecast 3: 16:00 - $2.01
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.00 (-3.38% ) |
| Volume | 0.117 mill |
| Avg. Vol. | 0.230 mill |
| % of Avg. Vol | 50.88 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ENTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ENTX
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Last 10 Buy Signals
Latest Press Releases
2024-04-08 08:30:00 - Press Release
Entera Bio Announces Publication Of Oral Pth(1-34) Peptide Tablets (eb613) Phase 2 Trial Data In The Journal Of Bone And Mineral Research
Jerusalem, april 08, 2024 (globe newswire) -- entera bio ltd. (nasdaq: entx), (“entera” or the “company”) a leader in the development of orally delivered peptides, announced today that data from the phase 2 trial of its lead clinical compound, eb613 (oral pth(1-34) tablets) for the treatment of post-menopausal women with low bmd or osteoporosis compared to placebo were published in the journal of bone and mineral research (jbmr).
2024-03-26 08:30:00 - Press Release
Entera Bio Announces Key Regulatory Milestone For Oral Pth(1-34) Peptide (eb613) Phase 3 Program: Fda Ruling On Qualifying Bmd As A Surrogate Endpoint For Osteoporosis Drugs Is Expected Within 10 Months
Jerusalem, march 26, 2024 (globe newswire) -- entera bio ltd. (nasdaq: entx) (“entera” or the “company”), a leader in the development of orally delivered peptides, announced today that the american society for bone and mineral research (asbmr) announced on march 25 2024 that the u.s. food and drug administration (fda) has communicated to the sabre (study to advance bmd as a regulatory endpoint) project team that a ruling to qualify the treatment-related change in bone mineral density (bmd) as a surrogate endpoint for fractures in future trials of new anti-osteoporosis drugs would be provided within 10 months.
2024-03-20 08:00:00 - Press Release
Entera Bio Announces Robust Pharmacokinetic Data For First-in-class Oral Glp-2 Peptide Tablet Treatment For Patients With Short Bowel Syndrome
Jerusalem, march 20, 2024 (globe newswire) -- entera bio ltd. (nasdaq: entx), (“entera” or the “company”) a leader in the development of orally delivered peptides, announced today positive pharmacokinetic results from its collaborative research combining a proprietary long acting glp-2 agonist developed by opko health, inc. (nasdaq: “opk”, or “opko”) with entera's proprietary n-tab™ technology.
2024-03-08 16:05:00 - Press Release
Entera Bio Announces Full Year 2023 Financial Results And Provides Business Updates
Jerusalem, march 08, 2024 (globe newswire) -- entera bio ltd. (nasdaq: entx), (“entera” or the “company”) a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended december 31, 2023.
2024-03-04 08:30:00 - Press Release
Entera Bio Regains Compliance With Nasdaq Minimum Bid Price Requirement
Jerusalem, march 04, 2024 (globe newswire) -- entera bio ltd. (nasdaq: entx), (“entera” or the “company”) a leader in the development of orally delivered peptides, announced today that it received notice from the nasdaq stock market llc (nasdaq) on march 1, 2024, informing the company that it has regained compliance with the minimum bid price requirement under nasdaq listing rule 5550(a)(2) (the “rule”) for continued listing on the nasdaq capital market and the matter is now closed.
Latest News
2024-04-18 19:20:25 - Zacks Investment Research
Why the Market Dipped But Entera Bio Ltd. (ENTX) Gained Today
In the closing of the recent trading day, Entera Bio Ltd. (ENTX) stood at $2.24, denoting a +0.9% change from the preceding trading day.
2024-04-15 15:43:32 - InvestorPlace
Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?
Wise investors are placing some biotech stocks on their watchlists this month, as these companies have surged over 160%. With more predicted upside to these companies than we see today, one could book some serious capital appreciation into a portfolio.
2024-04-12 10:41:03 - Zacks Investment Research
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
Here is how Entera Bio Ltd. (ENTX) and FibroGen (FGEN) have performed compared to their sector so far this year.
2024-04-09 10:11:07 - Zacks Investment Research
Here's Why You Should Invest in Entera Bio (ENTX) Stock Now
Here, we discuss some reasons why buying Entera Bio (ENTX) stock now may turn out to be a prudent move.
2024-01-30 08:30:00 - GlobeNewsWire
Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
JERUSALEM, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced that it will participate and be available for investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference being held February 13 – 14, 2024 in a virtual format.
2023-08-16 08:30:00 - GlobeNewsWire
Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting
JERUSALEM, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that it has been selected to present data for its investigational agent EB613 at the ASBMR 2023 Annual Meeting on October 13-16, 2023 in Vancouver, BC, Canada.
2023-05-05 18:57:11 - Zacks Investment Research
Entera Bio Ltd. (ENTX) Reports Q1 Loss, Misses Revenue Estimates
Entera Bio Ltd. (ENTX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.12.
2023-03-31 18:22:04 - Zacks Investment Research
Entera Bio Ltd. (ENTX) Reports Q4 Loss, Lags Revenue Estimates
Entera Bio Ltd. (ENTX) delivered earnings and revenue surprises of 16.67% and 86%, respectively, for the quarter ended December 2022.
2023-02-02 19:34:32 - Zacks Investment Research
Entera Bio Ltd. (ENTX) Flat As Market Gains: What You Should Know
Entera Bio Ltd. (ENTX) closed at $0.95 in the latest trading session, marking no change from the prior day.
2023-01-25 19:33:14 - Zacks Investment Research
Entera Bio Ltd. (ENTX) Flat As Market Sinks: What You Should Know
In the latest trading session, Entera Bio Ltd. (ENTX) closed at $0.95, marking no change from the previous day.